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Abstract: Echinocandin antifungals represent one of the most important drug classes for the treatment
of invasive fungal infections. The mode of action of the echinocandins relies on inhibition of the
β-1,3-glucan synthase, an enzyme essentially required for the synthesis of the major fungal cell
wall carbohydrate β-1,3-glucan. Depending on the species, echinocandins may exert fungicidal
or fungistatic activity. Apparently independent of this differential activity, a surprising in vitro
phenomenon called the “paradoxical effect” can be observed. The paradoxical effect is characterized
by the ability of certain fungal isolates to reconstitute growth in the presence of higher echinocandin
concentrations, while being fully susceptible at lower concentrations. The nature of the paradoxical
effect is not fully understood and has been the focus of multiple studies in the last two decades.
Here we concisely review the current literature and propose an updated model for the paradoxical
effect, taking into account recent advances in the field.
Keywords: echinocandin; caspofungin; micafungin; anidulafungin; paradoxical effect; paradoxical
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1. Introduction
Invasive fungal infections contribute significantly to the morbidity and mortality of
immunocompromised patients. Unfortunately, the arsenal of antimycotic drugs is very limited.
Current therapy of invasive fungal infections relies on primarily four antifungal drug classes:
the polyenes (i.e., amphotericin B), the azoles (e.g., fluconazole, posaconazole, and voriconazole),
the pyrimidine analogues (i.e., flucytosin), and the echinocandins (e.g., caspofungin, micafungin,
and anidulafungin). While polyenes and azoles directly or indirectly target the fungal membrane
and the antimetabolite flucytosin disturbs DNA and RNA synthesis, echinocandins interfere with
the fungal cell wall biogenesis by noncompetitively inhibiting the β-1,3-glucan synthase (β-GS, Fks1).
This enzyme is responsible for the synthesis of the major fungal cell wall carbohydrate β-1,3-glucan.
The β-GS is a multi-pass membrane protein that is located in the plasma membrane [1]. It is
assumed that the enzyme synthesizes a linear β-1,3-glucan polymer using UDP-glucose monomers as
a substrate [2,3]. Specialized enzymes may subsequently rearrange the β-1,3-glucan polymers, such as
by forming β-1,6-glucan linkages [4], which significantly contribute to the rigidity and dynamics of
the cell wall. Depending on the fungal species, approximately one-third to four-fifths of the cell wall
consists of β-1,3-glucan and its rearrangement derivatives [5].
Chemical inhibition of the β-GS or deletion of the underlying genes may have fatal consequences
for the organism. Yeasts that are lacking the enzymatic activity are typically not viable [6–9].
Because of this, echinocandins are usually considered fungicidal for susceptible (pathogenic) yeasts.
Resistance may occur, but, so far, was always associated with mutation in the β-GS itself [10].
It was proposed that these mutations do not impair the ability of echinocandins to bind to the
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enzyme but instead reduce the synthesis velocity [10–12]. The situation with filamentous fungi
in the genus Aspergillus is somewhat different. Echinocandins show only a fungistatic activity
against these molds [13]. Under in vitro conditions, this is reflected by incomplete growth inhibition,
accompanied by significant morphological changes in the mold’s hyphae. The lowest echinocandin
concentration that is able to provoke this morphological alteration is therefore called the minimal
effective concentration (MEC), which is in contrast to the minimal inhibitory concentration (MIC)
usually determined for antimicrobial agents. The reason for the limited activity of echinocandins
against Aspergillus has not been understood as for a long time β-1,3-glucan was believed to be essential
in all fungi. However, we could recently show that the pathogenic mold Aspergillus fumigatus is able to
survive and grow without β-1,3-glucan. Nevertheless, deletion of the β-GS in A. fumigatus has severe
consequences for the growth rate, morphotype, and conidiation (sporulation) [14].
In clinical settings, echinocandins show excellent antifungal activity against the most relevant
pathogenic Candida species and good antifungal activity against most Aspergillus species. The frequency
of echinocandin resistance is generally low, thereby making echinocandins a first choice for empiric
therapy of invasive candidiasis [15,16]. Moreover, echinocandins are recommended for second-line
therapy of invasive aspergillosis [16]. Phenotypic antifungal susceptibility testing is routinely
performed to avoid potential therapy failure. When performing susceptibility testing under
standardized conditions, e.g., with the broth microdilution method, a surprising echinocandin-specific
phenomenon called the “paradoxical effect” can be observed. This paradoxical effect is characterized
by the ability of certain strains to grow in the presence of higher echinocandin concentrations
(approximately 4 to 32 µg mL−1) while being fully susceptible at lower concentrations (approximately
0.03 to 1 µg mL−1). In the presence of very high concentrations (approximately >64 µg mL−1),
the fungal species showing the paradoxical effect become susceptible again [17–19]. The phenomenon
was observed with multiple species in the genera Candida and Aspergillus [20–22]. Within this review
we will summarize and discuss the current knowledge and recent advances related to the paradoxical
effect of the echinocandins.
2. The Paradoxical Effect: Dependence on Species, Strain, and Echinocandin Derivative
A paradoxical effect of an echinocandin was described for the first time in 1988. Hall and
colleagues reported for the nonclinical echinocandin cilofungin that many isolates of Candida albicans
and Candida tropicalis continued to grow in concentrations above that of partial inhibition [17]. Later on,
this phenomenon was also observed for other echinocandins and further fungal species, including
molds of the genus Aspergillus [20–22]. Interestingly, not every echinocandin derivative seems to
have the same capability to evoke the paradoxical effect. Of the three derivatives in clinical use,
namely caspofungin, micafungin, and anidulafungin, caspofungin was most frequently associated
with paradoxical growth in Candida spp. [18,21–25]. For example, of approximately 120 clinical
Candida dubliniensis isolates that were tested by Fleischhacker et al., 90% showed paradoxical growth
with caspofungin, 63% with micafungin, but none with anidulafungin [22]. Similar observations were
made with different isolates of Aspergillus spp. [20,26]. Of 11 clinical isolates six showed paradoxical
growth with caspofungin, two with micafungin, and five with anidulafungin [20,26]. However, it has to
be stated that the frequency of the paradoxical effect reported for the individual echinocandins but also
for isolates of different fungal species differs greatly between different studies (Table 1). For example,
paradoxical growth of C. albicans in the presence of caspofungin was observed by Chamilos et al. in 12
of 20 clinical isolates (60%) and by Fleischhacker et al. in only 14 of 101 clinical isolates (14%) [21,22].
A recently published study systematically assessed the occurrence of the paradoxical effect for a large
number of Candida isolates (n = 602) treated with caspofungin, anidulafungin, and micafungin [24].
Again, the results regarding the frequency and drug dependency differed in some cases for the
individual species when compared to previous studies (Table 1). The authors of this study proposed
that the discrepancies in results could be related to methodological differences between the studies
such as the chosen definition of paradoxical growth or the in vitro testing protocols, which were
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either EUCAST (European Committee on Antimicrobial Susceptibility Testing)- or CLSI (Clinical and
Laboratory Standards Institute)-based and apply different media [24].
Table 1. Manifestation frequency of the paradoxical effect in vitro in percent (%) of caspofungin (CS),
micafungin (MI), and anidulafungin (AN) among clinical isolates of selected Candida and Aspergillus
species in different studies. The numbers of tested isolates (n) are given in brackets. Paradoxical growth
was determined with CLSI (Clinical and Laboratory Standards Institute)-[21–23], EUCAST (European
Committee on Antimicrobial Susceptibility Testing)-[24], or metabolism-based [20] broth microdilution
methods in RPMI 1640-based media.
Study C. albicans(CS/MI/AN)
C. glabrata
(CS/MI/AN)
C. tropicalis
(CS/MI/AN)
C. dubliniensis
(CS/MI/AN)
C. parapsilosis
(CS/MI/AN)
A. fumigatus
(CS/MI/AN)
A. terreus
(CS/MI/AN)
A. flavus
(CS/MI/AN)
Chamilos et al. [21] 60/0/40(n = 20)
0/0/0
(n = 10)
40/70/20
(n = 10)
90/0/0
(n = 10)
Antachopoulos et al. [20] 55/18/45(n = 11)
63/13/25
(n = 8)
13/0/0
(n = 8)
Fleischhacker et al. [22] 14/0/0(n = 72–103)
90/63/0
(n = 124–127)
Shields et al. [23] 60/13/23(n = 30)
0/0/0
(n = 34)
4/0/0
(n = 23)
Marcos-Zambrano
et al. [24]
10/<1/11
(n = 291)
0/2/3
(n = 62)
62/38/48
(n = 50)
6/1/1
(n = 164)
3. Factors That Influence the Manifestation of the Paradoxical Effect
Apart from the chosen echinocandin and the examined species and strain, several additional
external factors influence the manifestation of the paradoxical effect. These include the media
composition, media additives but also the exact culturing conditions such as steadiness of the
echinocandin concentration, the presence of additive chemicals or physical stress, or growth in a
planktonic versus sessile phase. For example, Stevens et al. have shown that paradoxical growth
of C. albicans is more pronounced in synthetic amino acid medium-fungal (SAAMF) compared to
RPMI 1640 medium, and less pronounced in yeast nitrogen base medium (YNB). Since RPMI 1640
and SAAMF are both buffered to physiologic conditions, the differences do not solely depend on
the pH [18]. Supplementation of RPMI 1640 with a high concentration of serum (50%) was shown
to abolish the paradoxical effect of caspofungin. Interestingly, a lower serum concentration (10%)
did not abolish but rather drastically increased the concentration required to induce the paradoxical
effect [23]. At the same time, the MIC of caspofungin was not (10%) or only moderately (50%) affected
by serum [18,23]. Lewis and colleagues reported that supplementation of RPMI with 5% mouse serum
can suppress the paradoxical effect of caspofungin on A. fumigatus. However, these results should be
considered with some caution because they are solely based on measuring the metabolic activity of
Aspergillus mycelium [27]. In another study, 50% serum was able to suppress paradoxical growth of
A. fumigatus and other Aspergillus species [28]. Notably, the effect of serum on the MIC or MEC (in
the case of Aspergillus spp.) of echinocandins is controversial and was summarized and discussed
elsewhere [29].
Another factor that was repeatedly reported to affect the occurrence of a paradoxical effect is
sessile growth within a biofilm as compared to conventional growth as planktonic cells [25,30,31].
Melo et al. analyzed the manifestation of the paradoxical effect for several isolates of C. albicans,
C. tropicalis, C. parapsilosis, C. orthopsilosis, and C. metapsilosis. Interestingly, paradoxical growth
was more frequently observed when the isolates were grown as biofilms (24 of 30 isolates; 80%)
compared to planktonic cells culturing conditions (12 of 30 isolates; 40%). Besides this, individual
isolates also had a different concentration range for the occurrence of the paradoxical effect when
grown as a biofilm [30]. These results were confirmed by Ferreira et al. [31]. Later, Walraven et al.
performed similar experiments with clinical Candida isolates that harbor defined echinocandin
resistance mutations in the fks1 gene, which encodes the β-GS. As expected, the echinocandin MICs of
the different isolates were significantly increased when compared to susceptible strains. At the same
time, the majority of the isolates still demonstrated paradoxical growth in the presence of extremely
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high echinocandin concentrations. Again, manifestation of the paradoxical effect of individual isolates
depended significantly on the culturing condition (biofilm vs. planktonic) but also on the applied
echinocandin derivative [25].
An interesting factor that was reported to significantly influence the appearance of the
paradoxical effect is the steadiness of the echinocandin concentration. Stevens et al. already
observed that inconstant drug concentration, which may occur when testing the susceptibility with
a disc diffusion-like method on solid medium (agar), seems to suppress the paradoxical effect [18].
Similar observations were made by Shields et al. when investigating the postantifungal effect of
caspofungin. They found that removal of caspofungin after exposure in a time-kill assay abolishes
paradoxical growth. Interestingly, the intermittent exposure not only suppressed paradoxical growth
but additionally increased the fungicidal activity of caspofungin when compared to unaltered or
renewed drug exposure [32,33].
One important factor that determines the manifestation of the paradoxical effect is the
echinocandin concentration itself. Apparently, the effect is only manifest in a certain high concentration
range (approximately 4 to 32 µg mL−1) [17–19]. The reason for the absence of paradoxical growth
at concentrations below this range but above the MIC or MEC (approximately 0.03 to 1 µg mL−1)
is not known. However, we recently answered the question of why the paradoxical effect seems
to disappear at very high concentrations (approximately >64 µg mL−1). We could show that the
echinocandin caspofungin exerts additional antifungal activity against A. fumigatus besides inhibition
of the β-GS at very high concentrations [34]. This additional activity suppresses the growth of
otherwise paradoxically growing colonies and thereby explains the visual disappearance of the
effect [34]. The exact mechanism behind the additional antifungal activity, however, remains unknown.
Although possible alternative modes of action of echinocandins were proposed previously—for
example, inhibition of β-1,6-glucan synthesis or induction of apoptosis [35–37]—none has been further
elaborated or validated in successive studies.
4. The Clinical Relevance of the Paradoxical Effect
The question of whether the paradoxical effect is a mere in vitro phenomenon or could be
of relevance in a clinical setting for the treatment of fungal infections was repeatedly raised and
debated [18,33,38–40]. Unfortunately, this question still lacks a conclusive answer. So far, no clinical
data directly support the hypothesis that the paradoxical effect could interfere with antifungal
chemotherapy of candidiasis in humans [41–45]. Similar, the results of experimental studies in animal
models that explored the potential benefit of high-dose echinocandin therapy against Candida species
did not confirm the clinical relevance of the phenomenon [46,47]. On the contrary, several other
experimental studies in murine or rabbit invasive aspergillosis models that focused on the efficacy of
echinocandin dose escalation suggested a possible role of the paradoxical effect, mostly reflected by a
moderate increase in the fungal burden at higher doses [27,48–50]. A similar result was obtained in a
murine intraperitoneal candidiasis model in a study that specifically addressed the role of paradoxical
growth of a C. tropicalis isolate treated with caspofungin [51]. Interestingly, one study that investigated
the paradoxical effect in a neutropenic murine model of invasive aspergillosis specifically associated
the phenomenon with caspofungin and not with micafungin, which would be in good agreement
with the differing in vitro data for these two echinocandins [20,27]. Nevertheless, the repeatedly
described paradoxical effect in animal models finally appeared to not significantly affect the overall
survival [27,48–51].
Taken together, the evidence obtained with animal experiments suggests the occurrence of the
paradoxical effect under in vivo conditions. However, the clinical significance remains unknown. It has
to be noted that several of the paradoxical effect influencing the conditions mentioned above specifically
play a role under in vivo conditions. Serum or similar factors could possibly suppress the manifestation
of the effect. Continuous undulation of blood echinocandin levels during therapy as well as the chosen
echinocandin derivative (caspofungin vs. micafungin/anidulafungin) could hinder manifestation
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as well. On the other hand, factors such as growth as a sessile pathogen in a microbial biofilm,
a condition typically associated with catheter or implant infections, could facilitate a paradoxical effect
that subsequently promotes the persistence of the infection in a niche under high-dose echinocandin
therapy. Furthermore, clinically measurable significance might also be restricted to certain fungal
species. For example, while C. dubliniensis showed paradoxical growth in up to 90% of the tested
isolates [22], C. glabrata isolates almost never show the phenomenon [21,23,24]. Finally, the introduction
of new echinocandin derivatives with exceptionally long-lived pharmacokinetic profiles, such as the
echinocandin CD101 [52–55], could open up the question of whether the paradoxical effect manifests
in vivo under constantly high drug levels.
5. Mechanistic Insights and Possible Signaling Pathways Involved
Despite great efforts to determine the factors that promote or repress paradoxical growth,
the genetic and mechanistic basis of this phenomenon remains largely elusive. Many initial hypotheses
to explain the paradoxical effect could be excluded: It has been demonstrated that paradoxical growth
is not a result of resistance-associated mutations in the β-GS, upregulation of β-GS activity, inactivation,
precipitation or degradation of the drug, or selection of a resistant subpopulation [18,19,56].
It was repeatedly reported that exposure to inhibitory echinocandin concentrations triggers a
massive increase of cell wall chitin in Candida as well as in Aspergillus [14,34,56–60]. A similar drastic
increase in cell wall chitin was observed after inhibition of β-GS expression in A. fumigatus [14].
This demonstrated that fungi must have a conserved stress response pathway that induces chitin
synthesis upon depletion of cell wall glucan.
In fact, up to three signaling pathways were identified to upregulate chitin synthesis in response
to echinocandin treatment. First, Walker et al. found that in C. albicans the cell wall integrity (CWI),
the high osmolarity glycerol (HOG), and the calcineurin signaling pathways mutually stimulate
the chitin synthases Chs2 and Chs8 to overcome echinocandin-induced stress [59]. Similar results
were obtained for A. fumigatus. We have shown that disruption of the Wsc1 signaling branch of the
CWI pathway increases the susceptibility of A. fumigatus to echinocandins [61]. However, direct
evidence that links the susceptibility of such CWI signaling mutants with chitin synthesis is still
lacking. The increase in total chitin synthase activity in the presence of caspofungin has been shown
to be calcineurin-dependent [57]. This was revealed by analyses of A. fumigatus deletion mutants
of the calcineurin A catalytic subunit CnaA and the downstream calcineurin-responsive zinc finger
transcription factor CrzA. Interestingly, cnaA and crzA deletion mutants showed increased caspofungin
susceptibility and no paradoxical growth [57]. Later, Lamoth et al. demonstrated that heat shock
protein 90 (Hsp90) is involved in A. fumigatus calcineurin-dependent stress response to echinocandins.
Similar to the cnaA and crzA mutants, inhibition of Hsp90 function results in increased caspofungin
susceptibility and abolishes paradoxical growth [62,63].
Based on these results, it was tempting to speculate that the echinocandin-induced increase in cell
wall chitin mediates paradoxical growth. However, we have recently shown that the chitin levels of
paradoxically growing Aspergillus hyphae return to normal when compared to echinocandin-inhibited
but non-paradoxically growing hyphae [34]. Moreover, we found that the paradoxical effect depends
on expression of the β-GS and that paradoxically growing hyphae expose β-1,3-glucan again [34].
Importantly, the paradoxically growing hyphae show a rather normal morphology and emerge from
an initially growth-inhibited, β-1,3-glucan-depleted, chitin-rich and hyperbranched mycelium that
shows frequent hyphal lysis phenomena [14,34] (Figure 1). Interestingly, it takes approximately two to
three days before any paradoxical growth can be observed [34]. These results were also confirmed
by Moreno-Velásquez et al. [64]. Besides the switch in morphology, they showed that exposure
to growth-inhibitory echinocandin concentrations causes a mislocalization of the β-GS to vacuoles.
As soon as paradoxical growth begins, the β-GS showed renewed localization at the hyphal tips [64].
In summary, these data demonstrate that the paradoxical effect of echinocandins in the first line relies
on the reconstitution of the β-GS activity.
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Nevertheless, the initial increase in cell wall chitin that is regularly observed in
echinocandin-inhibited non-paradoxically growing fungi could represent an essential precondition.
It has been shown for multiple fungal species that inhibition of chitin synthesis strengthens the
fungicidal activity of echinocandins [23,65,66]. Consequently, the initial increase in cell wall chitin
facilitates survival of the organisms upon inhibition of β-1,3-glucan synthesis. Survival is, of course,
a prerequisite for the subsequent reconstitution of the β-GS activity and manifestation of the
paradoxical effect (Figure 1). Still, the mechanism by which the fungus reconstitutes β-1,3-glucan
synthesis remains unresolved.
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The interesting observation of Moreno-Velásquez et al. that the β-GS localizes to vacuoles under 
growth inhibitory caspofungin concentrations suggests that echinocandins could change the 
enzyme’s conformation, thereby committing inhibited β-GS to degradation. Renewed localization to 
the hyphal tips and reconstitution of β-1,3-glucan synthesis during paradoxical growth could then 
indicate a conserved mechanism to stabilize or protect newly synthesized β-GS. It is, however, 
surprising that the manifestation of such a salvage mechanism appears to significantly depend on the 
echinocandin derivative, occurs only in certain strains and species, and requires days to manifest.  
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Figure 1. Manifestation of paradoxical growth of A. fumigatus exposed to echinocandins. A limited
number of conidia do not survive germination in the presence of echinocandin antifungals.
Surviving microcolonies exposed to high echinocandin concentrations show a slow growth phenotype
characterized by hyperbranching, occasional lysis of hyphal compartments (colored compartments),
translocation of the β-GS to vacuoles, disappearance of cell wall β-1,3-glucan and co pensatory
increase of cell all chitin (blue cell alls). Regenerative intrahyphal gro th initiated fro the septa
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The interesting observation of Moreno-Velásquez et al. that the β-GS localizes to vacuoles under
growth inhibitory caspofungin concentrations suggests that echinocandins could change the enzyme’s
conformation, thereby committing inhibited β-GS to degradation. Renewed localization to the hyphal
tips and reconstitution of β-1,3-glucan synthesis during paradoxical growth could then indicate a
conserved mechanism to stabilize or protect newly synthesized β-GS. It is, however, surprising that
the manifestation of such a salvage mechanism appears to significantly depend on the echinocandin
derivative, occurs only in certain strains and species, and requires days to manifest. To this end,
many open questions remain about this mysterious echinocandin-specific phenomenon and should be
addressed in future studies.
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